~PROGRAM SCHEDULE
~
MORNING SESSION: 8:15 AM –
NOON
The morning session consists of a keynote speaker and
11 presentations by the following individuals with allotted time for
questions and answers after each presenter.
8:15-9:00 AM
KEYNOTE ADDRESS: Neurotropic Factors. Where Have We Been and
WHere Are We Going?
John Nutt. Oregon State Health University, Portland, Oregon.
9:00-9:15 AM
Motor Impairment in Normal Aging, Possible PD, and Definite
PD: Longitudinal Evaluation of a Cohort of Prospective Brain Donors.
C.H. Adler1, J.N. Caviness1, Marwan Sabbagh2, Don Connor2, J.G. Hentz1;
H. Shill3, V.G.H. Evidente1, M. Stacy3, J.N. Joyce2, Thomas Beach2.
1Mayo Clinic Scottsdale, Scottsdale, Arizona; 2Sun Health Research
Institute, Sun City, Arizona; 3Barrow Neurological Institute, Phoenix,
Arizona.
9:15-9:30 AM
Intravenous Flumazenil for Parkinson’s Disease: A Double
Blind, Placebo Controlled, Cross-Over Trial.
W.G Ondo, Y.S. Silay. Baylor College of Medicine, Houston, Texas.
9:30-9:45 AM
Role of Histamine H3 Receptors in L-DOPA-Induced Dyskinesia
and Psychotomimetic Behavior in the MPTP-Lesioned Non-Human Primate
Model of Parkinson’s Disease.
J. Gomez-Ramirez1, T. Johnston1,,J. Lee1, S. Fox2, J. Brotchie1. 1Toronto
Western Research Institute, University Health Network, Toronto, Ontario
Canada, 2Movement Disorders Clinic, Toronto Western Hospital, Toronto,
Ontario, Canada.
9:45-10:00 AM
PD Onset Symptoms Are Correlated with Family History.
M.B. Harrison, L.J. Currie, J.P. Bennett, Jr., J.M. Trugman, G.F. Wooten.
University of Virginia Health System, Charlottesville, Virginia.
10:00-10:15 AM
BREAK
10:15-10:30 AM
The Utility of [18F]FDOPA PET as an Endophenotype for Linkage
Studies of Parkinson Disease.
B.A. Racette, L.M. Good, J. Antenor, S. Moerlein, J.S. Perlmutter. Washington
University School of Medicine, St. Louis, Missouri.
10:30-10:45 AM
The Ubiquitous Mycotoxin Ochratoxin A Causes Dopamine Depletion
and Alterations in Oxidative DNA Repair in Striatum.
V. Sava2, A. Velasquez1,2, S. Song1,2, J. Sanchez-Ramos1,2. 1Neurology,
University of South Florida, Tampa, Florida, 2Research Service, James
Haley VA, Tampa, Florida.
10:45-11:00 AM
Development and Pilot Study of the First Non-motor Symptom Screening
Questionnaire and Scale for Parkinson’s Disease Using an International
Multidisciplinary Approach.
K.R. Chaudhuri1, A.H.V. Schapira2, P. Martinez-Martin3, K. Sethi4, G.
MacPhee5, R. Brown6, P. Odin7, W. Koller8, W. Olanow8 on behalf of the
International Non Motor Symptom Study Group. 1Kings College Hospital,
London, UK, 2Royal Free Hospital, London UK, 3Carlos III Institute of
Public health, Madrid, Spain, 4Medical College Georgia, Augusta, Georgia,
5Southern General Hospital Glasgow, UK, 6Institute of Psychiatry, London
,UK, 7Central Hospital Bremerhaven, Germany, 8Mount Sinai Hospital,
New York, New York.
11:00-11:15 AM
A Novel Mutation in the Nurr1 Gene in Parkinson’s Disease.
D.A. Grimes1,2, F. Han2, M. Panisset3, L. Racacho2, F. Xiao2, D. E.
Bulman1,2. 1Ottawa University, Ottawa, Ontario, Canada, 2Ottawa
Health Research Institute, Ottawa, Ontario, Canada, 3McGill University,
Montreal, Quebec, Canada.
11:15-11:30 AM
Apomorphine as Rescue Therapy of “Off” Episodes
in Patients with Advanced Parkinson’s Disease: A Pooled Efficacy
Analysis.
H.H. Fernandez1, R. Pahwa2. 1University of Florida/McKnight Brain
Institute, Gainesville, Florida, 2University of Kansas Medical Center,
Kansas City, Kansas.
11:30-11:45 AM
Selegiline Modifies the Disease Progression in Early Parkinsonian
Patients.
S.E. Pålhagen and the Swedish Parkinson Study Group. Karolinska
University Hospital Huddinge, Stockholm, Sweden.
11:45-NOON
- LATE BREAKING RESEARCH
In Vivo Study of Metabolic Brain Function in Parkinsonian Macaques
Following GAD Therapy.
M. Carbon-Correll1,2, M. Emborg3, Y. Ma1,2, J. Holden4, J. Kordower3,
A.S. Feigin1,2, M. During6, M. Kaplitt5, D. Eidelberg,1,2. 1Center
for Neurosciences, North Shore-Long Island Jewish Research Institute,
Manhasset, New York, 2Department of Neurology, New York University School
of Medicine, New York, New York, 3 Rush Presbyterian Medical Center,
Chicago, Illinois, 4 University of Wisconsin, Madison, Wisconsin, 5
Weill-Cornell Medical Center, New York, New York, 6 Department of Molecular
Medicine & Pathology, University of Auckland, Auckland, New Zealand.
NOON-1:30 PM
LUNCH
AFTERNOON SESSION: 1:30 PM –
5:00 PM
The afternoon session consists of a keynote speaker
and 10 presentations by the following individuals with allotted time
for questions and answers after each presenter.
1:30-2:15 PM
KEYNOTE ADDRESS: Fragile X-associated Tremor/Ataxia Syndrome
in a Premutation Carrier Population.
Paul Hagerman. University of California – Davis, Davis, California.
2:15-2:30 PM
The Clinical Course of Fragile X-associated Tremor/Ataxia Syndrome
(FXTAS).
M.A. Leehey1, D. Hall1, C. Rice1, S. Jacquemont2, L. Zhang3, J. Grisby1,
P.J. Hagerman3, R.R. Hagerman2. 1University of Colorado Health Sciences
Center, Denver, Colorado, 2M.I.N.D. Institute, University of California
at Davis Medical Center, Sacramento, California, 3University of California
at Davis School of Medicine, Davis, California.
2:30-2:45 PM
A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine
in Patients with Huntington’s Disease.
Huntington Study Group (F.J. Marshall, presenter1). University of
Rochester, Rochester, New York.
2:45-3:00 PM
Substantia Nigra Degeneration and Rotational Behavior in Rats
Post Tau or Tau/alpha Synuclein Gene Transfer.
M. Harper1, R. Zweig1, R. Dayton1, W.L. Lin2, D.W. Dickson2, R.L. Klein1.
1LSU Health Sciences Center, Shreveport, Louisana, 2Mayo Clinic,
Jacksonville, Florida.
3:00-3:15 PM
BREAK
3:15-3:30 PM
Efficacy and Safety of Repeated Doses of Botulinum Toxin Type
B in Type A Resistant and Responsive Cervical Dystonia Patients.
S.A. Factor1, E.S. Molho1, S. Evans1, P.J. Feustel2. 1Parkinson’s
Disease and Movement Disorders Center of Albany Medical Center, Albany,
New York, 2Division of Neurosurgery, Albany Medical Center, Albany,
New York.
3:30-3:45 PM
The Interrupted Structure of Expanded ATTCT Pentanucleotide
Repeats in SCA10 Patients.
R. Gao1, X. Lin1, W. Xu1, T. Matsuura2, T. Ashizawa1. 1Department
of Neurology, The University of Texas Medical Branch, Galveston, Texas,
2Department of Molecular and Human Genetics, Baylor College of Medicine,
Houston, Texas
3:45-4:00 PM
Clinical Efficacy and Video Analysis of Deep Brain Stimulation
for Medically Intractable Tourette Syndrome.
B.N. Maddux, D.E. Riley; C.M. Whitney, R.J. Maciunas. Case Western
Reserve University and University Hospitals of Cleveland, Cleveland,
Ohio.
4:00-4:15 PM
Focal Task-Specific Dystonia (FTSD) of the Hand in Musicians:
Is There a Link Between Task and Disease Expression?
A.M. Conti1, S.J. Frucht2. 1Neurology Residency Program, Washington
University, St. Louis, Missouri; 2The Neurologic Institute, Columbia
University Medical Center, New York, New York.
4:15-4:30 PM
Methadone for Dopaminergically Refractory Restless Legs Syndrome
(RLS).
W.G. Ondo. Baylor College of Medicine, Houston Texas
4:30-4:45
PM
Vertical Gaze Enhanced with Biofeedback for Patients with Progressive
Supranuclear Palsy: Evidence for Movement Related Plasticity in a Chronic
Progressive Neurological Disorder.
R.P. Di Fabio1, C. Zampieri1, P. Tuite2, J. Konczak3. 1Department
of Physical Medicine & Rehabilitation, 2Department of Neurology,
School of Medicine, & 3School of Kinesiology, University of Minnesota,
Minneapolis, Minnesota.
4:45-5:00 PM - LATE BREAKING RESEARCH
SCA12 Neuropathology: Cerebral Cortical and Cerebellar Atrophy,
Purkinje Cell Loss, and Neuronal Intranuclear Inclusions.
E. O’Hearn1,2, O. Pletnikova3, S.E. Holmes4, J.Q. Trojanowski5,
R.L. Margolis4,1, J.C. Troncoso3,1. Johns Hopkins School of Medicine,
Departments of Neurology1, Neuroscience2, Pathology3, Psychiatry4, 5Center
for Neurodegenerative Disease Research Department of Pathology and Laboratory
Medicine University of Pennsylvania School of Medicine.
~POSTER PRESENTATIONS
~
Posters will be staffed on Sunday, October 3, 2004 from
Noon – 1:30 PM in Grand West Ballroom.
Poster 1 (OMD)
The "Cross" Signs in Patients with Multiple System
Atrophy (MSA). -Quantitative Study
K. Abe, T. Hikita, M. Yokoe, M. Mihara, S. Sakoda. Department of
Neurology Osaka University Graduate School of Medicine, Suita, Osaka,
Japan.
Poster 2 (PD)
Alterations of T Lymphocyte Populations in Parkinson’s
Disease.
Y. Baba1, A. Kuroiwa2, R. J. Uitti1, Z. K. Wszolek1, T. Yamada3. 1Department
of Neurology, Mayo Clinic Jacksonville, Florida, 2Department of Microbiology
and Immunology, Fukuoka University School of Medicine, Fukuoka, Japan;
3Department of Neurology, Fukuoka University School of Medicine Fukuoka,
Japan
Poster 3 (PD)
Cognitive Impairment Parallels Motor Progression in Parkinson’s
Disease.
H.H. Fernandez, G.P. Crucian, C.E. Jacobson IV, K.A. Freeman, N.S. Patel,
S.K. Munson, D. Bowers, M.S. Okun. University of Florida/McKnight
Brain Institute, Gainesville, Florida.
Poster 4 (OMD)
Chronic Bilirubin Encephalopathy in a Premature Infant Without
Marked Hyperbilirubinemia.
D.L. Gilbert1, M.A. McMahon2. 1Division of Neurology, Cincinnati
Children’s Hospital Medical Center, Cincinnati, Ohio, 2Division
of Pediatric Rehabilitation, University of Cincinnati, Cincinnati, Ohio.
Poster 5 (OMD)
Cardiac Sympathetic Innervation in Multiple System Atrophy and
Progressive Supranuclear Palsy.
S. Gilman, D.A. Raffel, R.A. Koeppe, R. Little, H. An, L. Junck, M.
Heumann. University of Michigan, Ann Arbor, Michigan.
Poster 6 (PD)
Disclosing the Diagnosis of Parkinson’s Disease: Patient
Experiences
S. Haines1, H. Chen2, K.E. Anderson1,2, P.S. Fishman1, L.M. Shulman1,
W.J. Weiner1, S.G. Reich1. 1Department of Neurology, 2Epidemiology
and Biostatistics, and 3Psychiatry, The University of Maryland School
of Medicine, Baltimore, Maryland.
Poster 7 (OMD)
Medical Treatment for the Fragile X-associated Tremor/Ataxia
Syndrome.
D.A. Hall1, C.D. Rice1, R.R. Hagerman2, P.R. Hagerman3, E. Berry-Kravis4,
M.A. Leehey1. 1University of Colorado, Denver, Colorado; 2M.I.N.D.
Institute, University of California at Davis Medical Center, Sacramento,
California; 3University of California at Davis Medical Center, Davis,
California, 4RUSH University Medical Center, Chicago, Illinois.
Poster 8 (PD)
Early Onset Parkinsonism in Heterozygous Parkin Mutation Carriers
R. Inzelberg1,2, P. Nisipeanu1, R. L. Carasso1,2, S. C. Blumen1,2, N.
Hattori3, Y. Mizuno3. 1Hillel Yaffe Medical Center, Hadera, Israel;
2Rappaport Faculty of Medicine, Tehnion, Haifa, Israel; 3Juntendo University,
School of Medicine, Tokyo, Japan
Poster 9 (OMD)
Safety and Efficacy of Tetrabenazine in the Treatment of Huntington’s
Disease and Other Choreas.
J. Jankovic, K.D. Vuong, C. Hunter. Baylor College of Medicine,
Houston, Texas.
Poster 10
(OMD)
Blockade of Kv3.4-Containing Channels within the Subthalamic
Nucleus has Antiparkinsonian Actions.
T.H. Johnston & J.M. Brotchie. Toronto Western Research Institute,
University Health Network, Toronto, Ontario, Canada.
Poster 11 (OMD)
Depression and Suicidality at Baseline in the Prospective Huntington
At Risk Observational Study (PHAROS).
E. Kayson1, M. Darnell1, J. Weber1, K. Biglan2, I. Shoulson1 and the
Huntington Study Group PHAROS Investigators1. 1University of Rochester,
Rochester NY; 2Johns Hopkins School of Medicine, Baltimore, MD; complete
listing of 43 PHAROS sites is available1
Poster 12 (OMD)
Sporadic Adult-onset Cerebellar Ataxia of Unknown Origin: Clinical,
Electrophysiological and Imaging Features.
T. Klockgether, M. Abele. Department of Neurology, University Hospital
Bonn, D-53105 Bonn, Germany
Poster 13 (PD)
Blockade of Gap Junction Attenuates Priming and Striatal Preproenkephalin-B
Expression in the 6-OHDA Lesioned Rat Model of L-DOPA-Induced Dyskinesia.
J Lee, P. Carlen, A.E. Lang & JM Brotchie. Toronto Western Hospital,
Toronto, Ontario, Canada.
Poster 14 (PD)
Freezing After Bilateral Subthalamic Nucleus Stimulation For
Parkinson’s Disease.
K.E. Lyons, S.B. Wilkinson, R. Pahwa. University of Kansas Medical
Center, Kansas City, Kansas.
Poster 15 (PD)
Effect of COMT Inhibitor Entacapone on Plasma Homocysteine Levels
in Levodopa-treated Rats.
Erkki Nissinen1, Helena Haapaniemi1, Pekka Rauhala2. 1Orion Pharma
Research, Espoo, Finland, 2University of Helsinki, Helsinki, Finland.
Poster 16 (PD)
Short Term Effects of Vibratory Stimulation of the Soles Synchronized
with the Step on Gait in Parkinson’s Disease.
P. Novak1, V. Novak2. 1Department of Neurology, Boston University,
Boston, Massachusetts, 2Division of Gerontology, Beth Israel Hospital,
Harvard Medical School, Boston, Massachusetts
Poster 17 (PD)
Differential Effects on the Upper and Lower Extremity with Unilateral
Deep Brain Stimulation.
M.S. Okun1, C. Haas2, J. Alberts2, J.L.Vitek2. 1Movement Disorders
Center, University of Florida, Gainesville, Florida, 2Emory University/Georgia
Tech, Atlanta, Georgia.
Poster 18 (OMD)
Fear and Panic Induced by Deep Brain Stimulation.
A. Shapira, D.P. Wint, D. Bowers, U. Springer, H.H. Fernandez, W.K.
Goodman, K.D. Foote, & M.S. Okun. Movement Disorders Center,
University of Florida, Gainesville, Florida.
Poster 19 (OMD)
Activity of the Human Cerebellar Thalamus Preceding Self-paced
Movements.
G. Paradiso1,2, D. Cunic1, J.A. Saint-Cyr1,3, T. Hoque1, A.M. Lozano1,3,
A.E. Lang1,2, R. Chen1,2. 1The Krembil Neuroscience Centre and Toronto
Western Research Institute, 2Division of Neurology and 3Division of
Neurosurgery, University of Toronto, Toronto, Ontario, Canada.
Poster 20 (PD)
Gender Differences in Parkinson’s Disease Presentation
in a Movement Disorder Clinic.
M.L. Rajput1, A. Rajput2, A.H. Rajput1,2. 1Saskatchewan Centre for
Parkinson’s Disease and Movement Disorders, Saskatoon, Saskatchewan,
Canada, 2University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Poster 21 (OMD)
Atypical Firing Rates and Pattern in the GPi of a Patient with
Tardive Dyskinesia.
J.K.H. Tang1, N. Mahant1, J.M. Schwalb2,4, W.D. Hutchison1,2,4, A.E.
Lang3, A.M. Lozano2,4, J.O. Dostrovsky1,4. 1Dept. of Physiology,
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada,
2Dept. of Surgery, Division of Neurosurgery, Toronto Western Hospital,
Toronto, Ontario, Canada, 3Movement Disorders Center, Toronto Western
Hospital, University Health Network, Toronto, Ontario, Canada, 4Toronto
Western Research Institute, Applied and Interventional Research, Toronto,
Ontario, Canada.
Poster 22 (OMD)
The Tremor Rating Scale (TRS).
R. Tintner1 for the Tremor Research Group. 1Baylor College of Medicine,
Houston, Texas.
Poster 23 (PD)
Proton MR Spectroscopy of Substantia Nigra in the Human Brain
at 4 Tesla.
G. Oz, P.J. Tuite, M. Terpstra, I. Tkac, P. Aia, J. Lowary, R. Gruetter.
University of Minnesota, Minneapolis, Minnesota.
Poster 24 (PD)
Up-regulation of Striatal Cannabinoid CB1 Receptors by Acute
and Repeated Levodopa Treatment.
K. Venderova, J. Gomez-Ramirez, J. Lee, T.H. Johnston, J.M. Brotchie.
Toronto Western Research Institute, Toronto, Ontario, Canada.
Poster 25 (PD)
BP897, a “Selective” Dopamine D3 Receptor Partial
Agonist, has Actions in Addition to Attenuation of D3 Transmission in
Modulating Locomotion Induced by L-DOPA in Monoamine Depleted Rats.
N.P. Visanji1, M.J. Millan2, J.M. Brotchie1. 1Toronto Western Research
Institute, Toronto, Ontario, Canada,. 2Department of Psychopharmacology
IDR Servier, Paris, France.
Poster 26 (PD) - LATE BREAKING RESEARCH
Donepezil for Dementia in Parkinson’s disease: A Randomized,
Double-Blind, Placebo Controlled, Crossover Study
B. Ravina1, M. Putt2 A. Siderowf3, J.T. Farrar2, M. Gillespie1, A. Crawley1,
H. Fernandez4, M. Treischmann5, S. Reichwein3, T. Simuni6. 1National
Institute of Neurological Disorders and Stroke; Rockville, Maryland,
2University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics;
Philadelphia, Pennsylvania, 3University of Pennsylvania, Department
of Neurology; Philadelphia, Pennsylvania, 4University of Florida at
Gainesville, Department of Neurology; Gainesville, Florida, 5Brown University,
Department of Neurology, Pawtucket, Rhode Island, 6Northwestern University,
Department of Neurology, Chicago, Illinois.
Poster 27 (PD) - LATE BREAKING RESEARCH
Suppression of L-DOPA Induced Dyskinesias in Advanced Parkinson’s
Disease by Continuous Subcutaneous Infusions of Apomorphine - Results
of Two Year, Prospective Follow-up.
P. Kanovský, K. Dagmar, M. Bareš, H. Klajblová, I.
Rektorová, I. Rektor. 1st Department of Neurology, Masaryk
University, Brno, Czech Republic.
Poster 28 (PD) - LATE BREAKING RESEARCH
Antidepressants in the Treatment of Hallucinations and Comorbid
Depression in Parkinson’s Disease.
V. Voon1, S. Fox2, A.E Lang2. Toronto Western Hospital, Toronto,
Ontario, Canada, 1Department of Psychiatry, 2Division of Neurology.
Poster 29 (OMD) - LATE BREAKING
RESEARCH
Long-term Follow-up of Bilateral GPi DBS for Huntington’s
Disease.
E. Moro, Y.-Y. Poon, S. Hung, P. Piboolnurak, A.M. Lozano, A.E. Lang.
University Health Network, Toronto Western Hospital, Toronto, Ontario,
Canada
Poster 30 (OMD) - LATE BREAKING
RESEARCH
Cerebellar Dysfunction Following Severe Topiramate-Associated
Hyperthermia
S.C. Galicia, S.L. Lewis, L. Verhagen. Department of Neurological
Sciences, Rush University Medical Center, Chicago, Illinois.
Poster 31 (OMD) - LATE BREAKING
RESEARCH
Defining the Essential Tremor Phenotype: Initial Symptoms and
Baseline Characteristics in a Clinical Cohort.
N.R. Whaley, J.D. Putzke, Y. Baba, Z.K. Wszolek, R.J. Uitti. Department
of Neurology Mayo Clinic, Jacksonville, Florida.
